A recent study indicates that people who stop using new slimming jabs like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who stop traditional diet and exercise regimens.
Published data in a prominent health publication demonstrates that while obese individuals often shed a large proportion of their body weight while using the jabs, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals buying such medications need to be informed of the danger of quick rebound weight gain when the medication is stopped," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery implies a return to pre-treatment weight within about one and a half years.
Analyzing Approaches
The analysis, which looked at dozens of studies involving thousands of patients, compared the results of GLP-1 agonists with conventional dieting.
The team emphasize that individuals who lose weight through dieting usually see a less rapid creep back—around 0.1 kg a month—post-intervention.
Understanding the Quick Regain
Nutrition scientists suggest the way of the jabs explains the heightened rebound.
These medications copy a natural hormone called GLP-1, which moderates appetite.
"Long-term administration of GLP-1 levels several times higher than normal may cause the system to produce less of its endogenous hormone, and could diminish sensitivity to its actions," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this hormone supplement results in hunger is unsuppressed, making overeating a significant risk."
A Lifelong Issue?
Health authorities suggest the jabs for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
A number of clinicians say that, considering the high risk of weight regain, the therapy is often life-long.
This view is supported by drug manufacturers, who say that the findings "highlight the long-term character of obesity," comparing it to managing conditions like high blood pressure.
Patient Accounts
Individuals who have come off the jabs report a powerful return of hunger.
"I experienced something flipping and you're instantly extremely hungry," described one woman.
This difficulty is compounded if users have not established sustainable dietary or behavioural modifications during treatment.
Growing Use
Figures suggest that millions of people in the UK have used these injections in the past year, with desire continuing to grow.
- Adoption is higher among females than males.
- The middle-aged demographic shows the greatest level of interest.
- Many access the drugs through private healthcare rather than the NHS.
In conclusion, researchers stress that while the jabs are powerful agents for shedding pounds, they are not a permanent solution and maintained weight loss likely depends on integrated behavioural management.
